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Abstract
Objectives: To examine whether exogenous pulmonary
surfactants (exPS) substitute for or merely supplement
endogenous pulmonary surfactants (enPS) by looking at
sequential changes in the surfactant proteins (SP) SP-A
and SP-D in alveolar pools.
Methods: Fourteen preterm infants with RDS treated
with an artificial surfactant were compared to five normal-
term infants without RDS who were treated with artificial
ventilation at birth.
Results: Immediately after birth, SP-A and SP-D were
essentially absent in the alveolar pools of the RDS group,
but were present at normal levels in the controls. Treat-
ment with exPS apparently stimulated enPS production.
Conclusions: In infants who responded well to exPS
therapy, the SP concentration reached essentially normal
levels within 48–72 h after birth.
Keywords: Endogenous pulmonary surfactants; exoge-
nous pulmonary surfactants; surfactant proteins.
Introduction
Infants with RDS are deficient in endogenous pulmonary
surfactant (enPS), i.e., all forms of surfactant protein (SP):
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SP-A, SP-B, SP-C, and SP-D. Artificial exogenous pul-
monary surfactant (exPS) preparations (e.g., Surfacten,
Curosurf, Survanta, Infasurf, Alveofact) are derived
from extracts of animal lungs, containing SP-B and SP-
C, but do not SP-A or SP-D w6x. Therefore, changes in
the concentration of the endogenously synthesized SP-
A and SP-D can be used as an indicator of enPS secre-
tion. Better understanding of the point in exPS treatment
at which the insufficient enPS begins to be secreted and
maintained is important for the optimal design of RDS
therapy. The purpose of this study was to analyze the
course of exPS treatment in preterm RDS infants and to
identify the time at which enPS secretion begins. We also
examined sequential changes in the concentrations of
SP-A and SP-D in alveoli pools to determine whether suf-
ficient amounts of enPS were secreted in the RDS group
(which received exPS treatment) as compared to a non-
RDS group.
Patients and methods
The infants were treated in the neonatal intensive care units at
Kyunghee University Hospital and Soonchunhyang University
Chonan Hospital between March 2004 and August 2004. The
RDS group consisted of 14 preterm infants (gestational
period: median 30 weeksq3 days, range 25 weeksq
5 days;33 weeksq2 days, birth weight: median 1010 g, range
720;1750 g) who were ventilated for RDS without antenatal
steroid treatment and were treated with an intra-tracheal instil-
lation of the exPS Surfacten, which is a modified bovine PS
preparation made from bovine lung PS and synthetic PL (Mit-
subishi Pharma Co., Japan). A single dose of Surfacten was
given within 3 h after birth in all cases of the RDS group. We
selected a control group (non-RDS) of full term newborns with
a normal physiological pool of SP. This group consisted of five
full term infants who were ventilated for central hypoventilation
due to perinatal asphyxia without primary lung pathology and,
therefore, did not receive exPS treatment.
Collection and preparation of bronchoalveolar
lavage samples
Bronchoalveolar lavage (BAL) was carried out essentially as pre-
viously described w15x; samples were taken by using the stand-
ardized distal wedge-catheter newborn BAL technique at 0, 24,
48, and 72 h after birth in both the RDS and non-RDS groups.
The infant was in the supine position with the face turned to the
left, and the oxygen saturation was maintained above 95%. An
F6-sized suction catheter was inserted through the intratracheal
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Figure 1 Comparison of surfactant protein SP-A (left) and D (right) densitometer in bronchoalveolar fluid of RDS group (ns5) and
control group (ns5) at 0 h after birth measured by the Western blot analysis with densitometer. Unit: unit of densitometer.
tube, and normal saline (1 mL/kg) was infused and then aspi-
rated immediately using a suction device. This procedure was
then repeated once. The supernatant was centrifuged at 500=g
for 5 min and stored at –708C. For analysis, the supernatant was
mixed with 15 mL of BNC buffer (10 mM sodium borate, pH 7.4;
150 mM NaCl, 3 mM CaCl2) and centrifuged successively at
500=g for 10 min at 48C and at 27000=g for 2 h. After adding
BNC 100 mL to the precipitate mix, it was stored at a temper-
ature of –208C.
Gel electrophoresis and immunoblot analysis
Samples were analyzed by SDS-polyacrylamide gel electropho-
resis using 12% NuPAGE Novex Bis-Tris gels with the XCell
SureLock Mini-Cell (Invitrogen Life Technologies, Carlsbad, CA).
Proteins were then transferred from the gel to nitrocellulose
membranes, which were blocked for 1 h with PBS plus 0.5%
BSA and 0.02% Tween 20 (Sigma, St. Louis, MO). SP-A and
SP-D were detected with antibodies from Santa Cruz Inc.
(Delaware, CA); membranes were incubated with primary anti-
bodies at 1:500 in PBS at 48C overnight. Blots were incubated
with peroxidase-conjugated secondary antibodies at 1:1000 in
PBS for 1 h at 48C and were developed using the Enhanced
Chemiluminescence Detection System (Amersham Bioscience,
Buckinghamshire, England).
Statistical analysis
Statistics were analyzed by using the SPSS 12.0 statistical
package; the two-tailed Student’s t-test and the Mann-Whitney
test were used for statistical comparisons. P-0.05 were con-
sidered to be statistically significant.
Results
Analysis of SP-A and SP-D concentrations
in the RDS and non-RDS groups
In the RDS group, SP-A and SP-D were either absent or
were only minimally present at birth. However, concen-
trations of SP-A and SP-D (as assessed by densitometer
units obtained from quantitative immunoblot analysis) in
the non-RDS group were significantly higher than those
of the RDS group (P-0.01). Figure 1 shows the mean
densitometry units obtained from a single SDS PAGE
panel of five cases in both the RDS and non-RDS groups.
We also used immunoblot analysis to examine SP-A
and SP-D expression at 0, 24, and 48 h after birth in the
RDS and non-RDS groups (Figure 2). Because the RDS
group received a dose of exPS within 3 h after birth, we
expected to see increased SP levels after 3 h. In the RDS
group, the level of both SP-A and SP-D was deficient at
0 h after birth, whereas in the non-RDS group, the level
was sufficient even at 0 h after birth.
Sequential increases in the ratio of SP-A and SP-D
concentrations in the RDS and non-RDS group
Figure 3 shows the sequential changes in the ratio of SP-
A and SP-D concentrations, as analyzed by densitometry
of immunoblot samples. The level of SP-A and SP-D in
the RDS group at 0 h after birth was arbitrarily set at one
to provide a basis for the comparison; data are presented
as a ratio of (units of SP-A or SP-D at x h after birth)/
(units of SP-A or SP-D at 0 h after birth). In the 14 sub-
jects in the RDS group, there was a significant increase
in the relative SP-A abundance at 72 h after birth; SP-A
levels at this time point were similar to those of the non-
RDS group at 72 h (P-0.01). Levels of SP-D increased
notably at the 48 h time point and reached concentra-
tions similar to those of the non-RDS group at 72 h. For
the non-RDS group, levels of SP-A and SP-D were
significantly higher than those in the RDS group starting
at 0 h after birth; this difference was maintained
continuously after birth.
Discussion
In human infants, the size of the PS pool can be esti-
mated by the dilutional isotope method, in which an iso-
tope-labeled PS component is introduced into the body
to track PS levels and estimates of the pool size are
made by assessing the amount of dilution of the isotope.
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Figure 2 Expression examples of SP-A (left) and D (right) by the Western blot analysis in RDS group (ns3) and non-RDS group
(ns3) at 0, 24, 48 h after birth.
Figure 3 Sequential changes of increasing ratio SP-A and D in
RDS group (ns14) and non-RDS group (ns5) after birth.
Unit means increasing ratio comparing the unit at 0 h as one
after birth in RDS group. *P-0.01.
In mothers, the PS pool size increases in late pregnancy,
then gradually decreases after birth to the normal post-
partum adult level w18x. In preterm infants with RDS, the
PS pool is very low (2–10 mg PL/kg body weight)
because of lung immaturity, especially of type II pneu-
mocytes w14x. Hallman et al. w11x and Griese et al. w9x
used the isotopic dilution method to measure PL in pre-
term infants with RDS and demonstrated an apparent
pool size of ;16 mg PL/kg. Another study measured
pool size in preterm infants with RDS by using an endo-
tracheally administered stable isotope in combination
with a treatment dose of surfactant (100 mg PL/kg), and
found that the endogenous PS PL pool size (before treat-
ment) was ;10 mg PL/kg w16x. Several studies exam-
ining the kinetics of PS synthesis showed that in both
human and animal infants with RDS, rates of PS synthe-
sis were low w2, 4, 5x. Animal studies showed a slower
rate of PS turnover in newborns as compared to adults,
and in human studies using stable isotopes, the surfac-
tant PL metabolism was slower in preterm infants with
RDS compared to term infants without lung diseases.
Taken together, the results of these studies suggested
that in preterm infants with RDS, the small alveolar
PS pool size, decreased rates of PS synthesis, and
decreased PS turnover rates could affect the pathogen-
esis of the disease w8–10x.
In RDS cases, enPS is deficient at birth; therefore, the
infants have insufficient PS and SP in their alveolar pool.
There are many commercially available exPS prepara-
tions that may supplement the insufficient enPS at birth.
We used a modified bovine surfactant, Surfacten, as an
artificial exPS replacement therapy in preterm infants
with RDS. Surfacten was developed by Fujiwara et al.
w8x in 1980, and used in 1990 w7x. Surfacten, which is a
mixture of natural PS (extracted from bovine lung) and
artificial PLs, has only SP-B and SP-C and lacks SP-A
and SP-D. When Surfacten is administered to RDS
infants, their SP is different from non-RDS infants who
have all four SPs in the endogenous alveolar pool. Thus,
monitoring the concentration of SP-A and D in the alveo-
lar pool can be used as an indicator of enPS secretion.
In this study, we found that infants in the RDS group
were deficient for PS, and a very notable difference in the
RDS levels of PS vs. those of the non-RDS group was
seen. Our data also suggested that exPS might stimulate
the production of SP-A and SP-D in the RDS group
(treated with artificial surfactants 3 h after birth). Although
the administration of exPS is routine for treatment of RDS
in preterm infants, there is little information regarding the
effects of exPS on enPS metabolism. A study of exPS
administration in animals found that it stimulated enPS
synthesis and increased PS pool size w3x. In a human
study that measured the concentration of SP-A and SP-
D in BAL fluid in preterm infants with RDS, data showed
that levels of SP-A and SP-D increased after treatment
with artificial exPS w13x. Since the exPS used in the treat-
ment did not contain SP-A, the data suggest that per-
haps the secretion of enPS, which contains SP-A was
stimulated by the administration of exPS.
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Other studies showed that in preterm infants, the
incorporation of 13C in the form of intravenous wU-13Cx
glucose into the alveolar PS phosphatidylcholine and pal-
mitate increased after treatment with artificial exPS w3,
10x. Results from our study suggest a similar finding:
both SP-A and SP-D were absent in the alveolar pools
of the RDS group immediately after birth, but concentra-
tions of SP-A and D increased after treatment with an
exPS preparation (without SP-A and SP-D). This sup-
ports the conclusion that exPS treatment in preterm
infants with RDS seems to stimulate enPS synthesis and
secretion. Additionally, because the mechanism that is
believed to function in the recycling of PS involves the
uptake of PS components by type II pneumocytes w12x
for degradation and recycling into newly synthesized PS
lipids or proteins w17x, we could also speculate that exPS
administration stimulates recycling of PS as well as de
novo synthesis.
The timing of enPS secretion after exPS therapy is an
important consideration in planning the optimal timing for
such therapy, but there have been few studies in either
humans or animals that examined this factor. Beresford
and Shaw w1x reported that concentrations of SP-A and
SP-D in BAL increased significantly at day 4 and day 7
in preterm infants who were ventilated for RDS and were
treated with natural and synthetic PSs. In this study, we
similarly saw that the enPS components SP-A and SP-
D, which were not present in the artificial PS adminis-
tered for treatment, were fully secreted in the alveolar
pool at 48–72 h after birth. We can infer that there
was a very close relation between the clinical course
observed after treatment of RDS and results of this study
(data was not shown). Taken together, the data showed
that the amount of enPS in infants with RDS was clearly
insufficient at birth, but seemed to be stimulated and
improved after treatment with exPS. Also, there are
substantial improvements in the alveolar pools of PS at
48–72 h after birth.
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